CD274 and non-small cell lung carcinoma: However, despite the development of targeted therapies, such as tyrosine kinase inhibitors (TKIs) and immunotherapies involving anti-PD-L1 monoclonal antibodies (mAbs), the prognosis for patients with NSCLC remains unfavorable, particularly for those diagnosed with advanced-stage disease (3–5).